Tocqueville Asset Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Tocqueville Asset Management’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,404	Closed	-$17K	–	726
2022 Q1	$17K	Buy	+3,404	New	+$21.4K	﹤0.01%	703
2021 Q4	–	Sell	-10,131	Closed	-$112K	–	776
2021 Q3	$112K	Sell	10,131 -1,100	-10%	-$13.8K	﹤0.01%	714
2021 Q2	$190K	Sell	11,231 -3,509	-24%	-$66.5K	﹤0.01%	716
2021 Q1	$387K	Sell	14,740 -4,280	-23%	-$195K	0.01%	592
2020 Q4	$688K	Buy	19,020 +7,173	+61%	+$259K	0.01%	494
2020 Q3	$419K	Buy	11,847 +3,007	+34%	+$131K	0.01%	523
2020 Q2	$375K	Buy	8,840 +6,547	+286%	+$441K	0.01%	535
2020 Q1	$183K	Buy	2,293 +246	+12%	+$19.7K	﹤0.01%	600
2019 Q4	$189K	Buy	+2,047	New	+$173K	﹤0.01%	708

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tocqueville Asset Management's EVFM Position: Q2 2022 in Review

Tocqueville Asset Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 3,404 shares — an estimated $17K sold.

Tocqueville Asset Management first reported a position in EVFM in Q4 2019 and held it in 9 quarters. The position peaked at $688K in Q4 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

Tocqueville Asset Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Tocqueville Asset Management sold 3,404 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $17K.
Tocqueville Asset Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2019 and held it in 9 quarters.
Tocqueville Asset Management's Evofem Biosciences, Inc. Common Stock position peaked at $688K in Q4 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Tocqueville Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.